Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis

Journal of Rheumatology

Volumn 30, Issue 4, 2003, Pages 714-719

  Singh, Gurkirpal ^a,b   Miller, Jeffrey D ^a   Huse, Daniel M ^a   Pettitt, Dan ^a   D'Agostino, Ralph B ^a,c   Russell, Mason W ^a  

^a Medical Research International   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Boston University   (United States)

Author keywords

Cardiovascular disease; Cost analysis; Costs; Hypertension; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ACCURACY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MODEL; MONTE CARLO METHOD; OSTEOARTHRITIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MONTE CARLO METHOD; OSTEOARTHRITIS; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; UNITED STATES;

EID: 0037383122     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. National Center for Health Statistics, Centers for Disease Control and Prevention, US Department of Health and Human Services. National Health and Nutrition Examination Survey, III, 1988-94. Hyattsville, MD: Division of Data Services, National Center for Health Statistics, US Centers for Disease Control and Prevention. Available from: www.cdc.gov/nchs/nhanes.htm [Cited 3 March, 2003].
2. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991;90:42S-7S.
3. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
4. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension: the risk in perspective. Drugs 1996;51:179-84.
5. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002;89:18D-25D.
6. Singh G, Krishnan E, Bharathi Lingala V. Increased case-fatality of acute myocardial infarction in patients with rheumatoid arthritis: Data from a large prospective study of 8,939 patients followed for 45,769 person-years [abstract]. Presented at the Annual European Congress of Rheumatology, June 12-15, 2002; Stockholm.
7. Cupples LA, D'Agostino RB, Kiely D. Section 34: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30 year follow-up. In: Kannel WB, Wolf PA, Garrison RJ, editors. The Framingham Study: An epidemiological investigation of cardiovascular disease. Bethesda, MD: 1987; National Institutes of Health; NIH Publication No. 87-2703.
8. Philips SJ, Whisnant J, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-59.
9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
10. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation 1991;83:356-62.
11. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-8.
12. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication; the Framingham Study. Stroke 1994;25:40-3.
13. Huse DM, Sytkowski PA, Russell MW, Drowns S, Hartz SC. Estimating the economic costs of inadequate blood pressure control among U.S. adults. Pharmacoepidemiol Drug Safety 1997;6 Suppl 2:S88.
14. Bureau of Labor Statistics. U.S. Consumer Price Index for All Urban Consumers. Current Series. Washington: U.S. Department of Labor; January 2001.
15. ALLHat Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-75.
16. Cooper SP, Hardy RJ, Labarthe DR, et al. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program. Am J Epidemiol 1988;127:387-403.
17. Perry HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000;284:465-71.